Devoted to solving challenges to human health
We focus on not only treating disease but also enhancing quality of life.
Dedicated to drug R&D
Focus on discovery of novel drugs to address unmet medical needs
Multiple & flexible business model
Using the Greater China Operation Platform as a springboard to global markets
August 5, 2024
NDA Submitted for TaiGen Influenza Antiviral TG-1000 in Mainland China
April 18, 2024
TaiGen Successfully Completes TG-1000 Phase III Study
March 31, 2020
R&D
Overcoming antibiotic resistance and other areas of high unmet medical need.
SEE MORE
February 25, 2020
About Us
A discovery-based and market-focused pharmaceutical company with experience in anti-infectives.
SEE MORE
April 9, 2020
Investors
Communicating with investors, cultivating long-term investor relations and highlighting corporate’s value.
SEE MORE
April 9, 2020
ESG
Society provides, so we give back to society. We operate in ways that enhance society and the environment, instead of contributing negatively to them.
SEE MORE